Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
Volume 2.50M
Average 0.30M
CNTB Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Connect Biopharma Holdings LimitedNASDAQ: CNTB
Cost of Revenue · Q4 FY2025 · quarter ended Dec 2025
Cost of revenue remains negative
Q4 FY2025 cost of revenue was $0, compared with $0 a year earlier.
Context
- Cost of revenue amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How CNTB compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Cost of revenue amounts to 0.0% of revenue for CNTB, versus a peer median of 91.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | €7.26M EUR | +133.7% | — | 24746.3% | |
| LTM Mar 2026 | $1.82M USD | -36.2% | — | 182.0% | |
| LTM Mar 2026 | $1.28M USD | -28.6% | -4.0% | 1.3% | |
IMAImageneBio Inc | LTM Mar 2026 | $780K USD | -95.0% | -74.8% | — |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $666K USD | — | — | — |
| LTM Mar 2026 | $40.17K USD | — | — | — | |
| LTM Mar 2026 | $35K USD | — | — | 0.5% | |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $20K USD | — | — | — |
| FY2025 | $0 USD | — | — | 0.0% | |
| Peer median (excluding CNTB) | — | -32.4% | -39.4% | 91.6% | |
Competitors are the stored peer set for CNTB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 26.03M | 64K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 26.03M | 64K |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 80.5M | 96.63M | 53M | 29.26M | 37.8M |
| Selling, General & Admin | 19.01M | 20.81M | 16.05M | 19.23M | 20.34M |
| Operating Expenses | 98.11M | 119.32M | 69.06M | 48.49M | 58.14M |
| Depreciation & Amortization | 634K | 1.03M | 720K | 660K | 704K |
| EBITDA | (201.36M) | (116.74M) | (61.27M) | (14.75M) | (54.58M) |
| EBITDA Margin | — | — | — | -56.6% | -85279.7% |
| Operating Income | (98.11M) | (119.32M) | (69.06M) | (22.45M) | (58.07M) |
| Operating Margin | — | — | — | -86.2% | -90740.6% |
| Interest Income | 97.67K | 1.56M | 5.2K | 4.45M | 2.27M |
| Interest Expense | 6.91K | 21.03K | 0 | 0 | 0 |
| Other Income / Expenses | (103.89M) | 1.52M | 7.07M | 7.05M | 2.79M |
| Income Before Tax | (202M) | (117.79M) | (61.99M) | (15.41M) | (55.28M) |
| Pre-Tax Margin | — | — | — | -59.2% | -86379.7% |
| Income Tax Expense | 266K | 298K | 120K | 223K | 197K |
| Net Income | (202.27M) | (118.09M) | (62.11M) | (15.63M) | (55.48M) |
| Net Margin | — | — | — | -60.0% | -86687.5% |
| EPS (Basic) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| EPS (Diluted) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| Weighted Avg Shares | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
| Weighted Avg Shares (Diluted) | 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
Connect Biopharma Holdings Limited
NASDAQ:CNTB
Intrinsic Alpha fair value
Locked
Current Price
$0.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.